Compare · DXCM vs TTOO
DXCM vs TTOO
Side-by-side comparison of DexCom Inc. (DXCM) and T2 Biosystems Inc. (TTOO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TTOO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 441.7x TTOO ($62.5M).
- Over the past year, DXCM is down 20.1% and TTOO is up 0.0% - TTOO leads by 20.1 points.
- DXCM has hit the wire 6 times in the past 4 weeks while TTOO has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 1 for TTOO).
- Company
- DexCom Inc.
- T2 Biosystems Inc.
- Price
- $71.54+1.52%
- $0.13-34.35%
- Market cap
- $27.61B
- $62.5M
- 1M return
- +2.57%
- +0.00%
- 1Y return
- -20.08%
- +0.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
T2 Biosystems Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest TTOO
- Amendment: SEC Form 25-NSE/A filed by T2 Biosystems Inc.
- SEC Form 25-NSE filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form NT 10-K filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- T2 Biosystems Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: SEC Form SCHEDULE 13G/A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form DEF 14A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.